News

FDA Approves Copanlisib for Relapsed Indolent Follicular Lymphoma

New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of copanlisib to treat patients with relapsed indolent follicular lymphoma (FL). The PI3K dual-isoform inhibitor, developed by Bayer, has been…

LRF Publishes Recommendations on Adolescent and Young Adult Lymphoma Research

Findings from the 2015 Lymphoma Research Foundation scientific symposium on adolescent/young adult (AYA) lymphomas have been published int he influential journal Blood Advances.  The paper, “Adolescent and Young Adult Lymphoma: Collaborative Efforts at Understanding Biology and Optimizing Care,” reviews lymphoma…